ARTICLE | Company News
Novartis buying IFM inflammasome unit less than a year after launch
April 1, 2019 5:15 AM UTC
Novartis will pay $310 million up front to acquire IFM Tre and its trio of NLRP3 antagonists. Shareholders of the inflammatory disease subsidiary are also eligible for up to $1.3 billion in milestones.
IFM Therapeutics LLC (Boston, Mass.) launched IFM Tre Inc. in July with a $31 million series A round co-led by Atlas Venture, Abingworth, Bristol-Myers Squibb Co. (NYSE:BMY) and IFM’s management (see "IFM Launches Subsidiary with $31M Series A")...
BCIQ Target Profiles
NLR family pyrin domain containing 3 (NLRP3) (NALP3) (CIAS1)